Tysabri vs Entyvio for Crohn's: Comparing Integrin Biologics

Tysabri and Entyvio both target integrins in the pathway that drives immune cell trafficking in Crohn's disease, but they differ in which integrin subunit they block, and that difference creates profoundly different safety profiles. Entyvio (vedolizumab) is gut-selective and has a favorable safety record. Tysabri (natalizumab) blocks a broader integrin target that includes trafficking to the brain, creating a risk of progressive multifocal leukoencephalopathy (PML) that requires the TOUCH program to manage. This guide walks through the tysabri vs entyvio crohn's comparison.

Gut-Selective vs Systemic Integrin

Both drugs block integrin-mediated lymphocyte trafficking into inflamed tissue, but with different selectivity. Entyvio binds the alpha-4-beta-7 integrin heterodimer, a receptor found almost exclusively on gut-homing lymphocytes. By blocking only gut-selective trafficking, Entyvio quiets Crohn's inflammation without affecting lymphocyte trafficking to other tissues, including the central nervous system. Tysabri binds alpha-4 integrin generally, which affects both alpha-4-beta-7 (gut) and alpha-4-beta-1 (CNS) trafficking. This broader action explains Tysabri's PML risk. The natalizumab vs vedolizumab distinction is foundational to choosing between these two drugs.

Crohn's Efficacy

Entyvio's Crohn's efficacy was established in GEMINI 2 and GEMINI 3, showing meaningful clinical response and remission benefits over placebo. Tysabri's Crohn's efficacy rests on ENACT-1, ENACT-2, and ENCORE. No head-to-head trial has directly compared Tysabri with Entyvio in Crohn's. Indirect comparisons suggest similar efficacy in biologic-experienced patients, though the safety profile differences typically drive the choice decisively toward Entyvio for most patients.

PML Risk and TOUCH Program

Tysabri carries a black-box warning for PML, a rare but often fatal demyelinating brain disease caused by JC virus reactivation. Risk factors include prior immunosuppressant use, duration of Tysabri therapy beyond 2 years, and JC virus antibody positivity. The TOUCH program requires enrollment, JC virus antibody testing, routine monitoring, and prescriber/pharmacy/infusion center certification. Entyvio does not have the same PML risk due to its gut-selective mechanism. Rare PML cases have been reported on Entyvio, but at much lower rates than Tysabri. For PML risk biologic comparisons, Entyvio is substantially safer.

Safety Profile Comparison

Entyvio's gut-selective action produces very low rates of systemic infection, and its long-term safety data is among the cleanest of any IBD biologic for non-GI infections. A 2024 Swedish registry study flagged a higher rate of serious gastrointestinal infections on vedolizumab compared with anti-TNFs, though overall systemic infection risk was lower. Tysabri's safety profile is dominated by PML risk, which requires ongoing JC virus antibody monitoring and symptom surveillance. For tysabri vs entyvio side effects, Entyvio is the clear winner for the typical Crohn's patient.

Administration and Dosing

Entyvio starts with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks. After IV induction, Entyvio patients who respond can switch to a 108 mg SC pen every 2 weeks, according to Takeda's dosing information. Tysabri is administered as a 300 mg IV infusion every 4 weeks at a TOUCH-certified infusion center, per Biogen's prescribing information. Both require lifelong infusions, but Entyvio's every-8-week IV maintenance is less frequent than Tysabri's every-4-week schedule, and Entyvio offers SC conversion that Tysabri does not.

When Tysabri Might Be Considered

For Crohn's patients who have failed multiple biologic classes (anti-TNFs, IL-12/23, gut-selective, IL-23 p19), Tysabri may be considered as a treatment option, particularly in patients who test negative for JC virus antibodies (indicating lower PML risk). Tysabri can sometimes capture response in patients who have failed Entyvio, given its broader integrin targeting. This is a narrow population, and shared decision-making with a gastroenterologist experienced in refractory Crohn's is essential.

Practical Access

Entyvio infusions can be administered at a variety of infusion centers, and the SC pen can be self-administered at home after IV induction. Tysabri requires infusion at a TOUCH-certified center. TOUCH program enrollment adds administrative steps at initiation and ongoing visits. For patients with complex schedules or geographic barriers, Entyvio's accessibility is a practical advantage.

Biosimilar Availability

Tysabri has a biosimilar (Tyruko) approved in 2023, though real-world utilization in IBD remains low given the TOUCH program requirements apply equally to biosimilars. Entyvio is branded with no biosimilar currently on the US market.

Choosing With Your GI

For a Crohn's patient deciding between Tysabri and Entyvio, Entyvio is preferred for most patients because of its established role, favorable safety profile, SC conversion option, and absence of TOUCH program restrictions. Tysabri is a niche option reserved for patients who have exhausted other biologic classes including Entyvio and who test JC virus antibody negative. If you are considering Tysabri, ask your GI about JC virus antibody status, prior treatment history, and the specific risk-benefit rationale. A log of stool frequency, urgency, abdominal pain, and any new neurological symptoms between visits is particularly important for patients on Tysabri.